Two different peptides in this set: CJC-1295 (No DAC), also called Modified GRF(1-29), and Ipamorelin (NNC 26-0161). This is an identity fact, not a product claim.
Form Labs research guidePlain-English research guideModified GRF (1-29) / NNC 26-0161
CJC-1295 No DAC and Ipamorelin research guide
Everything worth knowing, without the jargon.
Jette et al. (Endocrinology, 2005) reported findings for CJC-1295 with DAC, separate from the no-DAC material listed here. Raun et al. (European Journal of Endocrinology, 1998) reported Ipamorelin measurements in animals. Neither compound is an approved medicine in this guide's record.
Form Labs materials are research reference materials, not the approved medicines; no Form Labs product is approved for human or veterinary use.
REV 2026-10 ยท 1 Oct 20263 peer-reviewed studiesResearch-use-only context
What the papers reportThird-party literature - not product claims
The year Ipamorelin was first described (Raun and colleagues). This is a research-history fact, not a product claim.
Raun et al., European Journal of Endocrinology, 1998Ipamorelin is a five-amino-acid (pentapeptide) agonist at the ghrelin receptor (GHS-R1a). This is an identity fact, not a product claim.
Raun et al., 1998; Howard et al., Science, 1996Why it matters
Why are CJC-1295 No DAC and Ipamorelin studied?
Jette et al. (2005) reported longer persistence for CJC-1295 with DAC, a form that binds albumin. That finding does not describe CJC-1295 (No DAC). Raun et al. (1998) reported Ipamorelin results in animal experiments, including growth hormone and stress hormone measurements. The papers cover separate compounds and models. They do not give a clinical result for the pair.
Two peptides, two parts of the GH axis.
This guide keeps two things apart. One is the DAC-modified compound studied by Jette et al. (2005). The other is the animal Ipamorelin work reported by Raun et al. (1998). Neither paper shows a clinical result for the listed pair.
Jette et al. (2005) reported albumin binding and longer persistence for CJC-1295 with DAC. The results do not describe the no-DAC material. Raun et al. (1998) reported growth hormone and stress hormone measurements in animal experiments with Ipamorelin. The papers do not show a clinical result for the pair.
The source guide keeps study context apart from Form Labs product claims.
Study observations
What laboratory observations have CJC-1295 No DAC and Ipamorelin studies reported?
Jette et al. (2005) reported longer persistence for CJC-1295 with DAC, a form that binds albumin. That finding does not describe CJC-1295 (No DAC). Raun et al. (1998) reported Ipamorelin results in animal experiments, including growth hormone and stress hormone measurements. The papers cover separate compounds and models. They do not give a clinical result for the pair.
Separate CJC-1295 and Ipamorelin records Findings stay tied to the cited study and its model.
DAC distinction
Jette et al. (2005) reported albumin binding and longer persistence for the DAC-modified compound. This is background, not direct no-DAC evidence.
Receptor identification
Howard et al. (1996) found a growth hormone secretagogue receptor in pituitary and hypothalamic tissue. This is a receptor study.
Ipamorelin animal observations
Raun et al. (1998) reported growth-hormone release in animals without a significant rise in ACTH or cortisol at the levels studied. The response was reduced, not removed.
Pharmacology at a glance
- Research code
- Modified GRF (1-29) / NNC 26-0161
- Class
- two distinct peptides - a short-acting GHRH analog (CJC-1295 No DAC / Modified GRF(1-29)) and a ghrelin-receptor agonist (Ipamorelin / NNC 26-0161). Class here means the research category that the source guide names.
- Molecule
- Two-material research record. CJC-1295 (No DAC), also called Modified GRF(1-29), is a short-acting, lab-made analog of growth hormone releasing hormone. Ipamorelin, also called NNC 26-0161, is listed separately. It is a five-amino-acid agonist at the ghrelin receptor (GHS-R1a). Neither supplies growth hormone directly.
- Reported half-life
- Not listed in the source guide for this entry. Half-life is the time it takes for a measured amount to fall by half.
- Originator
- Not listed in the source guide. Form Labs did not run the cited studies.
- Approval status
- Neither CJC-1295 (No DAC) nor Ipamorelin is an approved medicine. Neither is on the Australian Register of Therapeutic Goods. The TGA has not evaluated either for safety, quality or effectiveness. Ipamorelin's clinical development was discontinued. Both are on the World Anti-Doping Agency (WADA) Prohibited List. Both are supplied strictly as lab research materials, not for human use.
What it has been studied for
What have CJC-1295 No DAC and Ipamorelin been studied for?
CJC-1295 (No DAC) and Ipamorelin research covers three study areas. The first is the long-acting 'with DAC' form of CJC-1295 and how it binds albumin. The second is the ghrelin receptor GHS-R1a, where Ipamorelin acts. The third is the first description of Ipamorelin as a selective growth hormone secretagogue (a compound that prompts growth hormone release). The first area is background, not direct no-DAC evidence. All three are records of pathway or identity.
Study areas from the published literature.
CJC-1295 'with DAC' background
Study topic: the long-acting 'with DAC' form of CJC-1295 and how it binds albumin. It is context for the no-DAC material on this page. It is not direct no-DAC evidence.
Jette et al., Endocrinology, 2005Ipamorelin receptor context
Study topic: the ghrelin receptor (GHS-R1a) where Ipamorelin acts. A receptor is a cell signal receiver.
Howard et al., Science, 1996Ipamorelin identity
Study topic: the first description of Ipamorelin as a selective growth hormone secretagogue. It is an identity record, not a use instruction.
Raun et al., European Journal of Endocrinology, 1998The studies
What did the CJC-1295 No DAC and Ipamorelin studies find?
The three studies behind this guide are lab and animal work, not human trials. Jette et al. (2005) described the long-acting 'with DAC' form of CJC-1295. Howard et al. (1996) found the ghrelin receptor GHS-R1a, where Ipamorelin acts. Raun et al. (1998) first described Ipamorelin as a selective growth hormone secretagogue.
Open any study for a plain summary, what it measured, the finding, and a link to the paper.
The paper on how the long-acting 'with DAC' form of CJC-1295 was built to last in the bloodstream. It is background for this page. It is not evidence about the short-acting no-DAC material listed here.
- Studied in
- Lab binding experiments and animal studies.
- Design
- The researchers attached a chemical group, the DAC, to a GHRH analog. The DAC lets the peptide latch onto albumin, a carrier protein in the blood. They then compared how long the modified peptide lasted against the plain version.
- Measured
- How long the peptide stayed detectable in the bloodstream, and whether growth-hormone release followed.
The DAC-modified version lasted far longer than the plain GHRH analog (Jette et al., 2005). Riding on albumin let it escape the fast breakdown that clears these peptides within minutes. This is why the difference matters here. The material on this page is the short-acting no-DAC form. So this paper's results on lasting longer do not describe it.
DOI 10.1210/en.2004-1286The paper that found the receptor Ipamorelin acts on, before anyone knew the body's own signal for it.
- Studied in
- Pituitary tissue, with the receptor then made in cultured cells.
- Design
- The researchers worked backwards from compounds already known to trigger growth-hormone release. They hunted for the cell-surface receptor those compounds bound to, then cloned it.
- Measured
- Whether the cloned receptor responded when those compounds were applied to cells carrying it.
They found a new receptor, later named GHS-R1a, that is separate from the known GHRH receptor (Howard et al., 1996). At the time it was an orphan receptor, a lock with no known key. Ghrelin, the body's own molecule that fits it, was not found until 1999. Ipamorelin acts at this receptor. That makes it a very different kind of compound from CJC-1295.
DOI 10.1126/science.273.5277.974The paper that first described Ipamorelin. It made the case that Ipamorelin was unusually selective.
- Studied in
- Cultured pituitary cells plus animal studies.
- Design
- Ipamorelin was compared with other growth hormone secretagogues. The authors looked at whether growth hormone was released, and at which other hormones moved at the same time.
- Measured
- Growth-hormone release, alongside ACTH and cortisol. These are two stress axis hormones that the earlier secretagogues tended to disturb.
At the amounts that released growth hormone, Ipamorelin did not cause a significant rise in ACTH or cortisol (Raun et al., 1998). The earlier secretagogues tended to move these two stress axis hormones. In this study the response was reduced, not removed. That selectivity is why Ipamorelin kept appearing in later research. Its clinical development was still discontinued. It is not an approved medicine.
DOI 10.1530/eje.0.1390552Evidence and limitations
What does the CJC-1295 No DAC and Ipamorelin research mean, and what does it not?
This CJC-1295 (No DAC) and Ipamorelin guide is a map of the literature, not a product claim. The cited papers give identity, pathway and lab method context. The results on lasting longer come from the 'with DAC' form of CJC-1295. They do not come from the no-DAC material. Where the source gives no participant counts or study details, this page does not invent them.
The source guide is a literature map, not a product claim
The cited papers give background on identity, pathway, markers, models and lab methods. They are not Form Labs results or promises.
Study details are limited to the source record
The source guide may give no participant counts, model details, study amounts or study-stage labels. This page does not invent them.
Label and available report
Follow the product label and any verified matching COA for storage and batch decisions. Source storage note: Use the product label and any available report..
Lab handling
How are CJC-1295 No DAC and Ipamorelin handled as reference material?
CJC-1295 (No DAC) and Ipamorelin are lab reference material. They are not for human consumption or veterinary use. Storage and lot checks follow the product label and any verified matching certificate of analysis (COA). This guide's catalogue record notes storage at 2-8 C and protection from light.
Research-use boundary
Follow the product label and laboratory procedures for storage.
Educational boundary
This guide sums up third-party research. Form Labs did not run the cited studies.
Research-use boundary
For laboratory research use only. 21+ only. Not for human consumption or veterinary use.
Glossary
Plain-English definitions.
- GHRH
- Growth-hormone-releasing hormone. It is the natural hormone that a GHRH analog is built to resemble.
- GHRH analog
- A lab-made molecule built to resemble growth hormone releasing hormone. CJC-1295 (No DAC) / Modified GRF(1-29) is one example.
- Modified GRF(1-29)
- The research name for the no-DAC form of CJC-1295. It is a short-acting, lab-made GHRH analog that covers amino-acid positions 1 through 29.
- DAC
- Drug Affinity Complex. It is a binding tag on the 'with DAC' form of CJC-1295. The tag attaches to albumin in the blood and makes the half-life longer. The no-DAC form on this page does not have it.
- Growth-hormone secretagogue
- A compound studied for prompting the body's own release of growth hormone. Ipamorelin is one example. Such compounds do not supply growth hormone themselves.
- GHS-R1a
- The ghrelin receptor, which is a cell signal receiver. Ipamorelin acts at it.
- Ghrelin
- A hormone that acts at the GHS-R1a receptor. This guide names it only to identify the pathway Ipamorelin acts on.
- Glucose measurements
- Insulin-like growth factor 1. It is a marker linked to growth hormone in endocrine research.
- Pentapeptide
- A peptide made from five amino acids. Ipamorelin is a pentapeptide.
- COA
- Certificate of analysis. It is the batch paperwork that controls identity, purity, appearance and release checks.
- Research use only
- A lab-only boundary. It means not for human consumption, or for veterinary, medical or cosmetic use.
- Literature context
- A plain summary of what the cited papers discuss. It is not a product result.
FAQ
What are the most common questions about CJC-1295 No DAC and Ipamorelin?
CJC-1295 (No DAC) is a short-acting GHRH analog, also called Modified GRF(1-29). Ipamorelin is a five-amino-acid ghrelin-receptor agonist, also called NNC 26-0161 (Raun et al., 1998). The common questions cover the difference between 'with DAC' and 'no DAC', what a growth hormone secretagogue is, and Australian status. Both are lab research materials.
CJC-1295 (No DAC) is a synthetic analog of growth hormone releasing hormone (GHRH), also called Modified GRF(1-29). It is a short-acting peptide studied in the lab for the GHRH signalling pathway. It is a reference material for research use only, not an approved medicine.
'With DAC' and 'no DAC' are two forms of CJC-1295. The 'with DAC' form carries a Drug Affinity Complex that binds albumin in the blood, so it acts for longer. The 'no DAC' form (Modified GRF(1-29)) is short-acting and clears quickly. This page lists the no-DAC form. The limited human data reported by Teichman and colleagues (2006) were for the DAC form.
Ipamorelin is a selective growth hormone secretagogue. It is a five-amino-acid peptide that acts as an agonist at the ghrelin receptor (GHS-R1a). Raun and colleagues first described it in 1998. It has been studied in the lab for the ghrelin-receptor pathway. Its clinical development was later discontinued, and it is not an approved medicine.
Raun et al. (1998) reported growth hormone release in animal experiments with Ipamorelin. They measured ACTH and cortisol alongside it. The word secretagogue is the research category in that paper. It is not an established clinical result for this reference material.
Jette et al. (2005) examined CJC-1295 with DAC. Raun et al. (1998) examined Ipamorelin in animals. These papers cover separate compounds and models. The DAC findings do not describe the no-DAC material. The separate records do not show a clinical result for the pair.
Raun et al. (1998) reported growth hormone release in animals. ACTH and cortisol did not rise significantly at the Ipamorelin levels studied. Jette et al. (2005) examined the DAC-modified CJC-1295 compound. This is separate from the no-DAC material. These are separate experimental records, not a combined clinical trial.
No. Neither CJC-1295 (No DAC) nor Ipamorelin is an approved medicine in Australia. Neither is on the Australian Register of Therapeutic Goods. The TGA has not evaluated either one for safety, quality or effectiveness. Ipamorelin's clinical development was discontinued. CJC-1295 has only limited early human data. Form Labs supplies both strictly as lab research materials.
Yes. Growth hormone releasing hormone (GHRH) analogs and growth hormone secretagogues are on the World Anti-Doping Agency (WADA) Prohibited List. This includes CJC-1295 and Ipamorelin. They are banned in and out of competition. Athletes under anti-doping rules should confirm the current status with WADA. Form Labs supplies both for lab research only, not for human use.
The October 2026 Poisons Standard (checked 1 October 2026) lists CJC-1295 (CAS No. 863288-34-0) and ipamorelin in Schedule 4 and in Appendix D, clause 5 - the appendix for poisons whose possession without authority is illegal. The TGA's April 2026 examples of unapproved peptide products name CJC-1295, and Sport Integrity Australia lists CJC-1295 and ipamorelin as prohibited in sport. Form Labs supplies CJC-1295 (No DAC) and Ipamorelin strictly as laboratory research material, not for human or veterinary use.
'For research use only' means CJC-1295 (No DAC) and Ipamorelin are supplied strictly as lab reference materials. They are for in-vitro research, not for use in or on humans or animals. They are not medicines, supplements or food. Everything on this page describes published research and the identity of this batch. It does not give instructions for use.
References
Every figure, sourced.
Educational references to third-party literature. Form Labs is unaffiliated with the study authors.
Plain note: CJC-1295 'with DAC' albumin-binding record. Citation: Jette et al., Endocrinology, 2005.. A DOI is a permanent link code for the article. DOI: 10.1210/en.2004-1286.
DOIPlain note: Ipamorelin ghrelin-receptor context record. Citation: Howard et al., Science, 1996.. A DOI is a permanent link code for the article. DOI: 10.1126/science.273.5277.974.
DOIPlain note: Ipamorelin identity and class record. Citation: Raun et al., European Journal of Endocrinology, 1998.. A DOI is a permanent link code for the article. DOI: 10.1530/eje.0.1390552.
DOICitations are provided for education only. No therapeutic, weight-loss, or efficacy claims are made.
How we produce these guides
These guides are written and maintained in-house by the Form Laboratories research team. They summarise published literature and link to the cited papers. Form Laboratories did not run those studies. They are not authored by a named clinician and are not medical advice.
Findings remain tied to the study population, model and limits. Cell and animal observations remain separate from clinical results. Everything we supply is research-use-only reference material, not for people or animals.
The product
Form Laboratories - CJC-1295 (No DAC) & Ipamorelin
Ready to see CJC-1295 (No DAC) & Ipamorelin?
- Check available reports and the tests they cover.
- Compare the listed compound, amount and lot with the report.
- Ships from Perth via Australia Post or CouriersPlease in plain packaging.
From
$80.00 AUD
10 mg - 2-8 C
Reference material for laboratory research only.
Related catalogue records
Compare nearby catalogue records.
These nearby records stay inside the research-only catalogue.
Research-use-only catalogue
Continue to the product record.
Review lot-facing product details, pricing, and checkout boundaries on the matching product page.
View CJC-1295 (No DAC) & Ipamorelin - from $80.00 AUD